Key Takeaways
- Sei Foundation is exploring the acquisition of 23andMe.
- The firm plans to store genetic data on blockchain for enhanced security.
- 23andMe filed for bankruptcy on Sunday after 18 years in business.
Just days after genetic testing company 23andMe filed for bankruptcy, Sei Foundation, the firm behind the Sei blockchain, has expressed interest in acquiring it.
The goal, according to Sei, is to protect the genetic data of 15 million Americans by storing it securely on blockchain.
But not everyone is convinced this is a good idea.
A Blockchain-Powered Future for Genetic Data?
Sei has outlined a roadmap that would integrate 23andMe’s genetic data into its blockchain network.
The idea is to give individuals control over their own data, allowing them to decide how it’s used and potentially profit from it.
“We believe user data sovereignty is a matter of national security,” Sei said in a statement. “When an American biotech pioneer faces bankruptcy, the personal genomic data of millions becomes vulnerable to parties that may not share the same values of transparency and open access.”
The news comes at a precarious time for 23andMe. Once a dominant force in the consumer DNA testing industry, the company has been under scrutiny for its handling of sensitive data.
A 2023 data breach exposed the personal information of nearly 7 million users, sparking legal action and regulatory scrutiny.
On March 23, 23andMe officially filed for bankruptcy, ending nearly two decades of business.
Crypto Community Questions Sei’s Ambitions
Sei’s proposal to store genetic data on blockchain has been met with skepticism.
Privacy advocates and members of the crypto community raised concerns over the security risks and ethical implications of storing sensitive DNA information on an immutable ledger.
“Data was already compromised in a hack, and you can buy it for next to nothing on the darknet,” one user pointed out.
Others raised legal hurdles. The Health Insurance Portability and Accountability Act (HIPAA) and other regulations impose strict controls on medical data, and some question how Sei plans to navigate these laws.
“Curious to see how this plays out and your plan to deal with HIPAA and DEA regulations,” another commenter wrote. “There’s a massive gap in healthcare data security, and blockchain could help—but not like this.”
Critics have also accused 23andMe of selling user data to pharmaceutical companies in the past, making the idea of a Web3-based genetic data marketplace even more contentious.
With questions piling up, Sei’s vision for 23andMe remains far from a done deal.
Whether the blockchain offers a legitimate solution or simply adds another layer of controversy to the company’s troubled history remains to be seen.
Prashant Jha is a seasoned crypto journalist based in Delhi, India, with a Bachelor’s Degree in Computer Science Engineering. Passionate about the evolving world of blockchain and cryptocurrencies, he has been a dedicated voice in the industry since 2018. Prashant’s expertise lies in regulatory reporting, where he unravels complex legal and financial developments with clarity and precision. Before joining CCN in 2024, he honed his craft at Cointelegraph, establishing himself as a trusted name in crypto journalism.
His coverage spans major industry events, including the high-profile collapses of FTX, Three Arrows Capital (3AC), and LUNA, offering readers insightful analyses of their regulatory and market implications. Prashant’s technical background enables him to bridge the gap between intricate blockchain technology and its real-world applications, making his work accessible to novices and experts.
Beyond his professional pursuits, Prashant is an avid music enthusiast, often exploring diverse genres to unwind. A sports lover, he has a particular passion for cricket and frequently engages in discussions about the game. His multifaceted interests and sharp journalistic instincts make him a valuable contributor to CCN, where he continues shaping the crypto landscape's narrative.
